AGC Inc. (OTCPK:ASGLY) Discusses on Life Science Business Q&A Session Call
Company Participants
Kazumi Tamaki – Executive Officer and GM of Corporate Communications & Investor Relations
Tadashi Murano – Senior Executive Officer & President of Life Science Company
Presentation
Kazumi Tamaki
Executive Officer and GM of Corporate Communications & Investor Relations
Ladies and gentlemen, thank you very much for joining us today for Q&A session of AGC’s Life Science business. I am Tamaki from PR and IR. It is my pleasure to serve you as [ EMC ]. Let me introduce the speaker of the day, our Senior Executive Officer and President of Life Science Company, Tadashi Murano.
Tadashi Murano
Senior Executive Officer & President of Life Science Company
This is Murano speaking. Thank you very much for joining us today.
Kazumi Tamaki
Executive Officer and GM of Corporate Communications & Investor Relations
First off, we would like to have Murano-san give you an outline of our Life Science business, followed by questions and answers. The materials to be used have been uploaded through our website. We plan to close the session at around 6:00 today. Thank you very much for your understanding. Murano-san, over to you.
Tadashi Murano
Senior Executive Officer & President of Life Science Company
Thank you very much for your time today. Once again, I am Murano, President of Life Science Company. We received several questions from you. And out of that, I’d like to give some accounts on 3 common questions that have been raised by our investors. Some parts will overlap with the QA for our financial calls. I ask you for your understanding.
First of all, about our operating profit revision. Back in August, we announced the downward revision of our performance. Life Science businesses include biopharmaceuticals. We have Colorado and Longmont in Colorado in the United States. And we’ve
